Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

被引：55

作者：

Patt, YZ

Hassan, MM

Lozano, RD

Ellis, LM

Peterson, JA

Waugh, KA

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Pharm, Houston, TX 77030 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[4] Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 03期

关键词：

hepatocellular carcinoma; thalidomide; angiogenesis;

D O I：

10.1097/00000421-200006000-00023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.

引用

页码：319 / 321

页数：3

共 17 条

[1] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].